The global increase in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects more than one-third of the general population and up to 70% of individuals with type 2 diabetes or obesity, is a critical public health challenge. Given that liver steatosis is often asymptomatic until the advanced stages of disease, early detection is essential to prevent its progression to fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma. However, liver biopsy, the gold-standard diagnostic method, is invasive, costly, and unsuitable for large-scale screening. As a result, noninvasive tests have emerged as practical alternatives, particularly in primary care settings, where early identification is most feasible. The present study explored current perspectives of noninvasive liver disease screening tools and their implementation in primary care. Serum-based indices, along with imaging techniques, have demonstrated promise in identifying patients with advanced fibrosis. Novel biomarkers, including the enhanced liver fibrosis test and Pro-C3, as well as emerging artificial intelligence-assisted diagnostic platforms, yield improved accuracy and risk stratification potential. Despite accumulating evidence supporting the clinical utility and cost-effectiveness of noninvasive tests, several barriers hinder their routine use in primary care settings, which include limited funding, lack of standardized guidelines, insufficient clinician training, and disparities in access to diagnostic tools. The implementation of structured stepwise screening models has demonstrated improved diagnostic efficiency and reduced unnecessary referrals. Future research should emphasize the integration of artificial intelligence, portable diagnostic devices, and personalized risk models to enhance early detection. Ensuring widespread adoption requires coordinated efforts in policy development, provider education, and health-system investment. Noninvasive screening tools offer a feasible and cost-effective pathway for the early detection of MASLD in primary care; however, their successful implementation depends on addressing logistical, educational, and systemic barriers.
Citations
Citations to this article as recorded by
A transdisciplinary framework for managing metabolic dysfunction associated steatotic liver disease Sania Kouser, Sanketh V. Sharma, Arun Bhanu, Subrahmanya Kumar Kukkupuni, Chethala N. Vishnuprasad Frontiers in Pharmacology.2026;[Epub] CrossRef
Alcohol Abstinence Is Associated with Regression of Non-Invasive Fibrosis Markers in Patients with Metabolic Syndrome: A 12-Month Prospective Study Daniela Mihăilă, Horațiu-Paul Domnariu, Doru-Florian-Cornel Moga, Carmen-Daniela Domnariu Journal of Clinical Medicine.2026; 15(6): 2257. CrossRef
Towards early detection and prevention: proactive screening strategies in primary care Su Hwan Cho Korean Journal of Family Medicine.2025; 46(6): 379. CrossRef
Metabolism-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition worldwide and affects nearly 30% of the global population. While traditionally associated with metabolic risk factors, such as obesity and insulin resistance, increasing attention is being directed toward socioeconomic and environmental determinants that contribute to disparities in MASLD prevalence and outcomes. Low-income populations often experience higher rates of MASLD owing to limited access to healthcare, poor diet quality, and reduced opportunities for physical activity. Conversely, high-income countries are witnessing a paradoxical rise in MASLD cases, driven by sedentary lifestyles and excessive consumption of ultra-processed foods. This review examined the effects of socioeconomic status, education, healthcare access, and environmental exposure on the epidemiology of MASLD. The findings revealed that individuals from lower socioeconomic backgrounds and migrant populations experience a disproportionately higher burden of MASLD due to systemic healthcare barriers, dietary transitions, and occupational exposure. Children and adolescents face increasing susceptibility owing to rising obesity rates, and geographic disparities highlight Europe as the most affected region, followed by Asia and North America. Given the growing public health impact of MASLD, addressing both socioeconomic and environmental determinants is essential. Future efforts should prioritize policy-driven interventions, including equitable healthcare access, lifestyle modifications, and research into novel therapeutic approaches to mitigate the disease burden and improve patient outcomes.
Citations
Citations to this article as recorded by
Rising burden of steatotic liver disease in women of childbearing age and projections to 2035 Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang JHEP Reports.2026; 8(1): 101646. CrossRef
Atraric Acid Mitigates Mitochondrial Dysfunction and Inflammation via AMPKα–PGC-1α Signaling in Metabolic-Associated Fatty Liver Disease Yannan Xiang, Zhihao Ma, Tianyue Guan, Hongyu Huang, Xinran Li, Zihan Xu, Panpan Zhao, Lei Wang Antioxidants & Redox Signaling.2026; 44(7-9): 332. CrossRef
Vitamin D and the metabolic-associated steatotic liver disease—type 2 diabetes axis: a scoping-narrative review of global evidence and emerging perspectives for Sub-Saharan Africa Bruno Basil Frontiers in Epidemiology.2026;[Epub] CrossRef
MASLD In Children - A Distinct Phenotype? Pervej Alom Barbhuiya, Manash Pratim Pathak Current Obesity Reports.2026;[Epub] CrossRef
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns Klaudia Nowak, Krzysztof Łupina, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura Current Pharmacology Reports.2026;[Epub] CrossRef
Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis Yusuf Yilmaz Frontiers in Pharmacology.2025;[Epub] CrossRef
A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada James Kim, Paolo Raggi, Anne‐Marie Carreau, Sean Wharton, Alice Y. Y. Cheng, Mark G. Swain Diabetes, Obesity and Metabolism.2025; 27(12): 6831. CrossRef
The association between neighborhood context, allostatic load, and metabolic dysfunction-associated steatosis liver disease in Mexican-origin farmworkers along the Southern Arizona US/Mexico border A. Maldonado, E. Torres, M. Flores, M. Rodriguez, E.A. Villavicencio, R. Torres, I. Castro, F. Torres, J.C. Loya, N. Alkhouri, S. Carvajal, Garcia SSM - Population Health.2025; 32: 101862. CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease Ralf Weiskirchen, Amedeo Lonardo International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Enhancing MAFLD Care: Efficacy of a Multidisciplinary Community Intervention on Self-Management and Hepatic Outcomes Huan-Jing Cai, Hai-Lun Liang, Lei-Yu Shi, Yi-Hui Rong, Jing Li, Yan Zhang, Rui-Fang Ma INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2025;[Epub] CrossRef
From steatosis to cirrhosis: the role of obesity in the progression of liver disease Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Implementation of noninvasive liver disease screening tools in primary care Klaudia Nowak, Adrian Nowak, Aleksandra Jabłońska, Anna Potaczek, Julia Salacha, Natalia Dardzińska, Jakub Janczura Korean Journal of Family Medicine.2025; 46(6): 381. CrossRef
First
Prev
